139 related articles for article (PubMed ID: 23354826)
1. The impact of utilization of early aneuploidy screening on amniocenteses available for training in obstetrics and fetal medicine.
Rose NC; Lagrave D; Hafen B; Jackson M
Prenat Diagn; 2013 Mar; 33(3):242-4. PubMed ID: 23354826
[TBL] [Abstract][Full Text] [Related]
2. Uptake of noninvasive prenatal testing at a large academic referral center.
Larion S; Warsof SL; Romary L; Mlynarczyk M; Peleg D; Abuhamad AZ
Am J Obstet Gynecol; 2014 Dec; 211(6):651.e1-7. PubMed ID: 24954652
[TBL] [Abstract][Full Text] [Related]
3. Utilization of available prenatal screening and diagnosis: effects of the California screen program.
Blumenfeld YJ; Taylor J; Lee HC; Hudgins L; Sung JF; El-Sayed YY
J Perinatol; 2012 Dec; 32(12):907-12. PubMed ID: 22402484
[TBL] [Abstract][Full Text] [Related]
4. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?
Chasen ST; McCullough LB; Chervenak FA
Am J Obstet Gynecol; 2004 Mar; 190(3):769-74. PubMed ID: 15042012
[TBL] [Abstract][Full Text] [Related]
5. First-trimester and second-trimester screening at a community hospital: experience from the first year of implementation.
Philipson EH; Callahan M; Jelovsek JE
Obstet Gynecol; 2008 Aug; 112(2 Pt 1):218-22. PubMed ID: 18669714
[TBL] [Abstract][Full Text] [Related]
6. Declining invasive prenatal diagnostic procedures: A comparison of tertiary hospital and national data from 2012 to 2015.
Johnson K; Kelley J; Saxton V; Walker SP; Hui L
Aust N Z J Obstet Gynaecol; 2017 Apr; 57(2):152-156. PubMed ID: 28295165
[TBL] [Abstract][Full Text] [Related]
7. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
8. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
9. Invasive prenatal diagnostic practice in Denmark 1996 to 2006.
Vestergaard CH; Lidegaard Ø; Tabor A
Acta Obstet Gynecol Scand; 2009; 88(3):362-5. PubMed ID: 19172424
[TBL] [Abstract][Full Text] [Related]
10. The impact of first-trimester screening on AMA patients' uptake of invasive testing.
Wray AM; Ghidini A; Alvis C; Hodor J; Landy HJ; Poggi SH
Prenat Diagn; 2005 May; 25(5):350-3. PubMed ID: 15906421
[TBL] [Abstract][Full Text] [Related]
11. Impact of first-trimester aneuploidy screening in a high-risk population.
Nadel AS; Likhite ML
Fetal Diagn Ther; 2009; 26(1):29-34. PubMed ID: 19816027
[TBL] [Abstract][Full Text] [Related]
12. [How to improve the screening and diagnosis of fetal aneuploidy?].
Ville Y
Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102
[TBL] [Abstract][Full Text] [Related]
13. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
Goncé A; Borrell A; Fortuny A; Casals E; Martínez MA; Mercadé I; Cararach V; Vanrell JA
Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
[TBL] [Abstract][Full Text] [Related]
14. [Prenatal diagnosis].
Miny P; Tercanli S; Gänshirt D; Holzgreve W
Ther Umsch; 1995 Dec; 52(12):792-800. PubMed ID: 8539649
[TBL] [Abstract][Full Text] [Related]
15. Comparison of combined, stepwise sequential, contingent, and integrated screening in 7292 high-risk pregnant women.
Guanciali-Franchi P; Iezzi I; Palka C; Matarrelli B; Morizio E; Calabrese G; Benn P
Prenat Diagn; 2011 Nov; 31(11):1077-81. PubMed ID: 21800336
[TBL] [Abstract][Full Text] [Related]
16. ACOG Committee Opinion #296: first-trimester screening for fetal aneuploidy.
Obstet Gynecol; 2004 Jul; 104(1):215-7. PubMed ID: 15229041
[TBL] [Abstract][Full Text] [Related]
17. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
Nakata N; Wang Y; Bhatt S
Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
[TBL] [Abstract][Full Text] [Related]
18. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
19. The use of prenatal ultrasound for the detection of fetal aneuploidy.
Holmgren C; Lacoursiere DY
Clin Obstet Gynecol; 2008 Mar; 51(1):48-61. PubMed ID: 18303499
[TBL] [Abstract][Full Text] [Related]
20. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
Widlund KF; Gottvall T
Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
